PEGS Boston Summit上將有70 多項來自世界領先製藥公司的研究發展。

聆聽業界先驅、思想領袖和開拓者的意見，獲得有助於推動業界發展和創新的獨特視角。

Manufacturing Properties of Engineered AAV versus Natural Serotypes
Lionel Galibert, Senior Principal Research Scientist, Biotherapeutics and Genetic Medicine, AbbVie

Genome-Scale Functional Genomics Screening Highlights Genes Impacting Protein Fucosylation in Chinese Hamster Ovary Cells
Chenlin Hsieh, PhD, Principal Research Scientist I, Genome Biology/Genomics Research Center, AbbVie

Protein Language Models Enable Prediction of Polyreactivity of Monospecific, Bispecific, and Heavy-Chain-Only Antibodies
Michail Vlysidis, PhD, Senior Engineer, AbbVie

Protein Production from HEK293 Cell Line-Derived Stable Pools with High Protein Quality and Quantity to Support Discovery Research
Benjamin Alba, PhD, Scientific Associate Director, Discovery Protein Science, Biologic Therapeutic Discovery, Amgen Inc.

Rational Combinations to Increase Impact of BiTE Immune Therapy in Solid Tumors
Julie M. Bailis, PhD, Associate Vice President, Oncology Research, Amgen

A Modality-Agnostic High-Throughput Mass Spectrometry Method: From Small Molecule Covalent Screening to Large Multispecific Antibodies, and Everything Else in Between
Iain D.G. Campuzano, PhD FRSC, Scientific Director, Molecular Analytics, Amgen, Inc.

Collection and Management of Binding Data to Support Development of AI and ML Training
Wei Wang, PhD, Principal Scientist, Therapeutic Discovery, Amgen, Inc.

Generating CD8-Selective T Cell Engager Molecules
Mark Cobbold, PhD, Vice President, Oncology Early Discovery, AstraZeneca Pharmaceuticals

Microfluidic Capture and Rapid Screening of Natively Paired B Cell Repertoires for the Discovery of Potent Biologics
Sarav Rajan, PhD, Senior Scientist, AstraZeneca

Immunogenicity and Hypersensitivity Assessment through Clinical Development
Karen Robbins, MD, Safety Physician and Clinical Lead, Immune Safety Knowledge Group, Patient Safety Oncology and Center of Excellence, AstraZeneca

Biophysical Characterization across Modalities
George Bou-Assaf, PhD, Associate Director, Analytical Development, Biogen

Analytical Development and Characterization of a Bispecific Antibody Therapeutic
Pamela Peng Feng, Scientist, Analytical Development, Biogen

ML-Based Digital Formulation Development
Nicholas Michelarakis, PhD, Postdoctoral Research Fellow, Boehringer Ingelheim Pharmaceuticals

Increasing Automated Expression and Purification Processes for Higher-Throughput Platforms
Felix Findeisen, PhD, Associate Director, Discovery Biotherapeutics, Bristol Myers Squibb

An Integrated System for the Full Automation of Analytical Method Performance Monitoring: A Case Study and Lessons Learned
Dan (Cassie) Liu, Principal Statistician, Bristol Myers Squibb

Pre-Clinical Immunogenicity Risk Assessment Strategy for Diverse Biological Modalities: Lead Selection and Mitigation
Jochem Gokemeijer, PhD, Senior Director, Molecular Discovery Technologies, Bristol-Myers Squibb

Potency Assay Development for a Novel Class of ADCs
Yuefeng Chen, Research Scientist, Eli Lilly & Co.

High-Throughput Biophysical Characterization and Comprehensive Analysis
Mahlet Woldeyes, PhD, Senior Advisor, Eli Lilly and Company

Revolutionizing Protein Expression and Production: Modular and Scalable Automation for Accelerated Drug Discovery at Genentech
Kanika Bajaj Pahuja, PhD, Senior Scientific Manager, Protein Sciences, Genentech Inc.

Pharmacological Analysis of Agonistic and Antagonistic FGFR1 MAbs Reveals a Similar Unique Mode-of-Action
Laetitia D. Comps-Agrar, PhD, Senior Principal Scientist, Biochemical & Cellular Pharmacology, Genentech, Inc.

Advanced Repertoire Mining Strategies for Antibody Optimization
Isidro Hotzel, PhD, Distinguished Scientist, Antibody Engineering, Genentech

Antibody Developability Assessment: End-to-End Automated Simulation Workflow for Predicting Physical and Chemical Stability
Saeed Izadi, PhD, Scientist, Early-Stage Pharmaceutical Development, Genentech, Inc.

Meaningful Biological Priors as Guiding Constraints for Graph Neural Network-Based Antibody Developability Prediction
Pranav M. Khade, PhD, Postdoctoral Fellow, Prescient Design, Genentech

A Single Point Mutation on FLT3L-Fc Protein Increases the Risk of Immunogenicity
Yinyin Li, PhD, Principal Scientist, Biochemical & Cellular Pharmacology, Genentech Inc.

Antibody-Mediated Delivery of PROTACs
Thomas Pillow, PhD, Senior Scientist, Genentech, Inc.

Measuring Solution-Phase Kinetics Using Solid-Phase SPR: Measuring the True Stability of the Ranibizumab-VEGF Complex
John Quinn, PhD, Distinguished Scientist, Biophysical Group, Biochemical and Cellular Pharmacology, Genentech

Complementary Bioanalytical Approaches for Characterizing Emerging Modality Therapeutics from Biomatrices
Rachel Liuqing Shi, PhD, Principal Scientist, Genentech, Inc.

Antibody Targeting of E3 Ubiquitin Ligases for Receptor Degradation
Felipe de Sousa e Melo, PhD, Senior Scientist, Oncology Bioinformatics, Genentech Inc.

Engineering and Preclinical Characterization of GS-8588, a Bispecific T-Cell Engager Targeting the HIV Reservoir
Nathan D. Thomsen, PhD, Director, Protein Therapeutics, Gilead Sciences Inc.

Targeting CCR8+ Tregs for Depletion in the Tumor Microenvironment Leads to Robust Anti-Tumor Immunity
Brian Weist, PhD, Senior Research Scientist II, Immunology, Gilead Sciences Inc.

Strategies for Overcoming Challenging Targets with in vivo Antibody Discovery
Trevor Wattam, PhD, Scientific Leader, Antibody Discovery, GlaxoSmithKline

Characterization of mAb Therapeutics Size Variants Using Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC)
Zahid Khan, MS, Biopharmaceuticals Investigator, R&D Analytical Development, GSK

Accelerating Drug Discovery: High-Throughput Semi-Automated Expression Platform for Antibody Lead Generation
Goncalo Silva, PhD, Senior Scientist, Biopharm Discovery, GSK

T Cell-Engaging Antibodies for the Treatment of Hematological Malignancies
Ulrike Philippar, PhD, Senior Director & Head, Oncology & Discovery Hematological Malignancies, Janssen Pharmaceutica NV

Assessing Expression-Ability of Complex Protein Modalities Using Biophysical-Mass-Spec Analytical Techniques
Hirsh Nanda, PhD, Director, Analytical Sciences, Janssen

Antibody Developability Prediction and Sequence Generation with AI/ML
Alan Cheng, PhD, Senior Director, Modeling and Informatics, Merck Research Labs

Accelerating Antibody Discovery through the Integration of AI/ML Methods with in-House Experimental Data
Nasser Hashemi, PhD, Senior Scientist, Discovery Biologics, Merck

Reigning in Therapeutic Protein Expression with Pichia pastoris
Adam Nylen, Senior Scientist, Merck & Co Inc.

Accelerating Discovery to FIH through Early Formulation Risk Assessments of Novel Biologics
Suman A. Luthra, PhD, Director, Discovery Pharmaceutical Sciences, Merck & Co. Inc.

Maximizing Recombinant Protein Quality and Quantity in Cells
Brian Meyer, PhD, Principal Scientist, Merck

A Machine Learning Strategy for the Identification of in silico Descriptors and Prediction Models for IgG Monoclonal Antibody Developability Properties
Andrew B. Waight, PhD, Senior Director, Machine Learning, Discovery Biologics & Protein Sciences, Merck Research Labs

End-to-End Bioanalytics and Life-Cycle Management for mRNA Therapeutics
Jason DelCarpini, Director, Bioanalytical and Molecular Assays, Moderna

Production of a Challenging Human Single-Pass ER Membrane Protein: Expression in Multiple Hosts and Screening of Novel Fusion Constructs for Solubility in Expi293
Ethan Dunn, Manager, Protein Sciences, Moderna, Inc.

Strategies for qRT-PCR Assay Development and Validation for Clinical PK Studies of mRNA Drug Products
Vasily Vagin, PhD, Associate Director, Molecular Bioanalytics, Moderna

Optimizing mRNA Therapeutics through MIDD
Linh Van, PhD, Head, Clinical Pharmacology and Pharmacometrics, Moderna

mRNA-Encoded Monoclonal Antibodies to Combat Infectious Diseases
Laura Walker, PhD, Head, Infectious Disease Biotherapeutic Discovery & Engineering, Moderna

New in silico Immunogenicity Profiling Approach-Based on Drug/Pathogen Analogy
Michael Gutknecht, PhD, Principal Scientist II, Novartis Pharma AG

Benefits and Challenges of MAM Implementation at Novartis
Thomas Pohl, PhD, Director, Analytical Characterization, Novartis Pharma AG

Biophysical Characterization of Bispecific Antibodies and Antigen-Antibody Complexes
Dennis Asberg, PhD, Project Manager, Global Research Technologies, Novo Nordisk A/S

High-Throughput Characterization of Antibodies in Early Research
Merika Reinau, Specialist, Global Research Technologies, Novo Nordisk

A Novel Approach to Scoring New LLMs (Large Language Models) in Biotherapeutic Development
Varsha Daswani, PhD, Data Science Business Lead, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc.

Prediction of Deamidation and Isomerization in Therapeutic Proteins Using Machine Learning Combined with Structural and Dynamical Features
Brajesh K. Rai, PhD, Senior Director, Machine Learning Computational Sciences, Pfizer Inc.

Exploring Parametric and Mechanistic Differences between Expi293F and ExpiCHO-S Cells for Transient Antibody Production Optimization
Jing Zhou, MS, Senior Scientist, BioMedicine Design, Pfizer Inc.

Bispecific ADCs: Modulating Intracellular Trafficking to Improve Efficacy
Julian Andreev, PhD, Research Fellow, Oncology & Angiogenesis, Regeneron Pharmaceuticals, Inc.

Developing a High-Throughput Serotype-Independent Capsid Titer Method to Support Accelerated AAV Formulation and Drug Product Development
Marilia Barros, PhD, Principal Scientist, Regeneron Pharmaceuticals

Clinical Case Studies of Different ADA Testing Strategies-What Do We Gain with 3 Tiers of Assessment?
Mu Chen, PhD, Principal Scientist, Bioanalytical Strategy Group, Regeneron Pharmaceuticals

A METxMET ADC for Cancer Therapy
John DaSilva, PhD, Associate Director, Oncology & Immune-Oncology, Regeneron Pharmaceuticals Inc.

Immunogenicity of Protein Therapeutics When Administered Intravenously vs. Subcutaneously
Kamalika Mukherjee, PhD, Principal Scientist, Bioanalytical Strategy, Regeneron Pharmaceuticals Inc.

Targeted Therapies for the Enhancement of Anti-Tumor T Cell Responses
Eric Smith, PhD, Senior Director, Bispecifics, Regeneron Pharmaceuticals, Inc.

Assessment of Size and Charge Variant Profiles for Complex Antibody Formats
Patrick Bulau, Control Strategy Scientist, Pharma Analytical Science and Global Quality Control, Roche Diagnostics GmbH

Enhancing Molecule Developability Studies with Automated Analytical Systems
Benjamin Weiche, PhD, Senior Scientist, Roche Diagnostics GmbH

Launching into the Future: Sanofi’s Biologics AI Moonshot Program-Advancing AI Strategy and Innovation for Biologics
Maria Wendt, PhD, Global Head and Vice President, Digital and Biologics Strategy and Innovation, Sanofi

Analytical Challenges and Strategy to Support a Low-Concentration in-Use Comparability Study
Yan Wang, PhD, Principal Scientist, Takeda

Immunogenicity Assessment Strategy for mRNA-LNP Therapeutics
Xiaobin Zhang, PhD, Principal Scientist, Takeda Pharmaceuticals